Table 1.
Demographic and Clinical Characteristics of Study Patients
| Characteristic | Active Clinic Cohort (n=3095) | Lost to Follow Up (n=940) | Random Sample Selected for Tracing (n=95) | Outcome Ascertained by Tracing or Surveillance (n=79) |
|---|---|---|---|---|
|
| ||||
| Age, years, median (IQR) | 44 (36 to 50) | 41 (33 to 48) | 41 (35 to 48) | 41 (35 to 48) |
|
| ||||
| Male, % (n/N) | 87.5% (2703/3089) | 89.2% (836/937) | 88.4% (84/95) | 88.6% (70/79) |
|
| ||||
| Race/ethnicity, % (n/N): | ||||
| Asian/PI | 5.7% (175/3095) | 4.7% (44/940) | 5.3% (5/95) | 3.8% (3/79) |
| Black | 21.8% (674/3095) | 20.9% (196/940) | 14.7% (14/95) | 13.9% (11/79) |
| Latino | 23.2% (718/3095) | 21.8% (205/940) | 17.9% (17/95) | 17.7% (14/79) |
| White | 46.9% (1452/3095) | 49.8% (468/940) | 59.0% (56/95) | 60.8% (48/79) |
| Other | 2.2% (68/3095) | 2.7% (25/940) | 3.2% (3/95) | 3.8% (3/79) |
| Unknown | 0.3% (8/3095) | 0.2% (2/940) | 0% (0/95) | 0% (0/79) |
|
| ||||
| CD4 T cell count, % (n/N): | ||||
| <200 | 11.1% (331/2977) | 12.6% (116/922) | 12.9% (12/93) | 13.0% (10/77) |
| 200–350 | 17.4% (517/2977) | 16.8% (155/922) | 15.1% (14/93) | 15.6% (12/77) |
| 351–500 | 21.1% (627/2977) | 22.5% (207/922) | 21.5% (20/93) | 22.1% (17/77) |
| >500 | 50.5% (1502/2977) | 48.2% (444/922) | 50.5% (47/93) | 49.4% (38/77) |
|
| ||||
| Viral suppression at last measurement prior to becoming lost to follow up (VL<200), % (n/N) | 77.5% (2371/3059) | 71.0% (655/923) | 81.9% (77/94) | 80.8% (63/78) |